ZNetwork on MSNOpinion
From Tariffs to Tribute: The $350B Price of ‘Parity’
On 29 October 2025, the carefully scripted pageantry of the US-ROK alliance in Gyeongju and Seoul met an unwelcome ...
Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback